二甲双胍对2型糖尿病合并胃癌患者生存期的影响

Effect of Metformin on Survival in Patients with Type 2 Diabetes Mellitus and Gastric Cancer

目的通过研究二甲双胍对2型糖尿病合并胃癌患者生存期的影响,为胃癌的临床治疗提供依据。方法选取2018年1月—2020年1月在该院诊断2型糖尿病合并胃癌的患者80例为研究对象,根据治疗糖尿病的方式不同分为两组观察组与对照组,各40例,两组患者均行胰岛素治疗,观察组在对照组基础上加入口服二甲双胍治疗。观察两组患者血糖控制情况及近期疗效。COX多因素回归分析对生存时间的影响,确定二甲双胍对胃癌患者生存期的影响。结果观察组治疗期间血糖指标空腹血糖、平均血糖波动、糖化血红蛋白分别为(7.23±1.72)mmol/L、(3.30±0.36)mmol/L、(4.34±1.69)%均低于对照组,差异有统计学意义(t=2.412、3.411、2.564,P<0.05)。二甲双胍是影响胃癌生存时间的主要因素。结论二甲双胍利于血糖的控制,二甲双胍是影响胃癌生存时间的主要因素。

Objective To study the effect of metformin on the survival of patients with type 2 diabetes mellitus and gastric cancer,and to provide evidence for the clinical treatment of gastric cancer.Methods A total of 80 patients with type 2 diabetes mellitus and gastric cancer diagnosed in the hospital from January 2018 to January 2020 were selected as the study objects.According to the different ways of treating diabetes,they were divided into two groups.Both groups were treated with insulin,and the observation group was treated with oral metformin on the basis of the control group.The blood glucose control and short-term curative effect of the two groups were observed.The effect of COX multivariate regression analysis on survival time was determined to determine the effect of metformin on the survival time of gastric cancer patients.Results The blood glucose indexes of fasting blood glucose,average blood glucose fluctuation and glycosylated hemoglobin in the observation group during treatment were(7.23±1.72)mmol/L,(3.30±0.36)mmol/L,(4.34±1.69)%lower than those in the control group,the difference was statistically significant(t=2.412,3.411,2.564,P<0.05).Metformin is a major factor affecting the survival time of gastric cancer.Conclusion Metformin is beneficial to the control of blood glucose,and metformin is the main factor affecting the survival time of gastric cancer.